Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CC Chemokine Receptor 2 Antagonists

Citations Over TimeTop 13% of 2007 papers

Abstract

Introduction of ring restrictions to a linear aminobutyramide CC chemokine receptor 2 (CCR2) antagonist lead (2) led to the discovery of a 1,3-disubstituted cyclopentane scaffold with enhanced hCCR2 receptor binding and antagonist activity. (1S,3R)-N-[3,5-Bis(trifluoromethyl)benzyl]-1-methyl-3-[(1R,3'R)-methyl-1'H-spiro[indene-1,4'-piperidin]-1'-yl]cyclopentanecarboxamide (16) had IC50 of 1.3 nM (binding) and 0.45 nM (functional chemotaxis) against hCCR2. It also showed activity against the mouse CCR2 receptor with an IC50 of 130 nM. Compound 16 is selective against other chemokine receptors, including CCR5 ( approximately 500-fold).

Related Papers

• → Blocking HIV‐1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor(2003)76 cited
• → Advances of CCR5 antagonists: From small molecules to macromolecules(2020)47 cited
• → Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview(2014)16 cited
• → HIV-1 Entry and Macrophage Inflammatory Protein-1β-mediated Signaling Are Independent Functions of the Chemokine Receptor CCR5(1997)183 cited
• → CCR5 Chemokine Receptor(2007)1 cited